ANI Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ANIP ANI Pharmaceuticals Inc
HBUV Hubilu Venture Corporation
LMNL Liminal BioSciences Inc
NXTD NXT-ID Inc
RIOT Riot Blockchain Inc
HIHO Highway Holdings Ltd
CBAY Cymabay Therapeutics Inc
DTSS Datasea Inc
MOXC Moxian Inc
EDRY EuroDry Ltd
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Closing Price
$29.86
Day's Change
0.25 (0.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
29.86
Day's Low
28.42
Volume
(Average)
Volume:
88,887

10-day average volume:
96,367
88,887

ANIP's position in the Pharmaceuticals industry

Industry PeersANIPCOLLBDSIAQSTACRX

Summary

Company ProfileANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The...
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology...
Go to COLL summary
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of...
Go to BDSI summary
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs...
Go to AQST summary
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include...
Go to ACRX summary
52-Week Change

VS. INDUSTRY
-64.59%
59.94%
17.72%
71.90%
-53.72%
Market Cap

VS. INDUSTRY
$368.5M
$571.7M
$445.7M
$191.1M
$100.6M
Beta

VS. INDUSTRY
1.3
0.8
0.6
--
1.8
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
--
--
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$203.4M
$298.7M
$129.9M
$48.7M
$2.4M
Profit Margin

VS. INDUSTRY
-0.67%
-4.21%
-5.01%
-139.64%
-2,302.53%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
-28.07%
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
-2.19%
2.58%
102.56%
-14.00%
16.26%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.